skip to main content
Idioma:

Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms

Lima, Keli ; Carlos, Jorge Antonio Elias Godoy ; Alves-Paiva, Raquel de Melo ; Vicari, Hugo Passos ; Souza Santos, Fábio Pires de ; Hamerschlak, Nelson ; Costa-Lotufo, Leticia Veras ; Traina, Fabiola ; Machado-Neto, João Agostinho

Scientific reports, 2019-07, Vol.9 (1), p.1-9, Article 9895 [Periódico revisado por pares]

London: Nature Publishing Group

Texto completo disponível

Citações Citado por
  • Título:
    Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms
  • Autor: Lima, Keli ; Carlos, Jorge Antonio Elias Godoy ; Alves-Paiva, Raquel de Melo ; Vicari, Hugo Passos ; Souza Santos, Fábio Pires de ; Hamerschlak, Nelson ; Costa-Lotufo, Leticia Veras ; Traina, Fabiola ; Machado-Neto, João Agostinho
  • Assuntos: Apoptosis ; Cell proliferation ; Cell viability ; Cytoskeleton ; DNA damage ; Janus kinase ; Janus kinase 2 ; Phenotypes ; Signal transduction ; Tumors
  • É parte de: Scientific reports, 2019-07, Vol.9 (1), p.1-9, Article 9895
  • Descrição: Abstract JAK2/STAT signaling participates in the Ph-negative myeloproliferative neoplasms (MPN) pathophysiology and has been targeted by ruxolitinib, a JAK1/2 inhibitor. In the present study, the impact of ruxolitinib treatment on cytoskeleton-related genes expression was explored. In SET2 cells, AURKA and AURKB expression/activity were downregulated in a dose- and time-dependent manner by ruxolitinib. Reversine, a multikinase inhibitor selective for aurora kinases, reduced cell viability in a dose- and/or time-dependent manner in JAK2 V617F cells. Reversine significantly increased apoptosis and mitotic catastrophe, and reduced cell proliferation and clonogenic capacity in SET2 and HEL cells. In the molecular scenario, reversine induced DNA damage and apoptosis markers, as well as, reduced AURKA and AURKB expression/activity. In SET2 cells, reversine modulated the expression of 32 out of 84 apoptosis-related genes investigated, including downregulation of antiapoptotic ( BCL2 , BCL2L1 , and BIRC5 ) and upregulation of proapoptotic ( BIK , BINP3 , and BNIP3L ) genes. Synergism experiments indicated that low dose of reversine had a potentiating effect under ruxolitinib treatment at low doses in SET2 cells. In summary, our exploratory study establishes new targets, related to the regulation of the cellular cytoskeleton, for potential pharmacological intervention in MPN. These findings indicate that AURKA and AURKB participate in the JAK2/STAT signaling pathway and contribute to the MPN phenotype.
  • Editor: London: Nature Publishing Group
  • Idioma: Inglês
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  10 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.